A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn*s Disease

Published: 27-01-2016
Last updated: 17-04-2024

Primary:* To obtain data on long term safety and tolerability on vedolizumab SC in subjects with Ulcerative Colitis (UC) or Crohn's Disease (CD).Secondary:* To obtain data on adverse events of special interest (AESIs; serious infections...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Gastrointestinal inflammatory conditions
Study type	Interventional

Summary

ID

NL-OMON55460

Source
ToetsingOnline

Brief title
Vedolizumab SC Open-Label Extension [MLN0002SC-3030]

Condition

- Gastrointestinal inflammatory conditions

Synonym
inflammatory bowel diseases, ulcerative colitis and Crohn's disease

Research involving
Human

Sponsors and support

Primary sponsor: Takeda
Source(s) of monetary or material Support: industry

Intervention

Keyword: Crohn's Disease, Maintenance Therapy, Ulcerative Colitis, Vedolizumab SC

Outcome measures

Primary outcome

Subject-year-adjusted treatment emergent AEs and SAEs during long-term vedolizumab SC treatment.

Secondary outcome

* Subject-year-adjusted AESIs during long-term vedolizumab SC treatment.

* Proportion of subjects with clinical response during long-term vedolizumab SC treatment using partial Mayo scores defined as a reduction in partial Mayo score of *2 points and *25% from Baseline with an accompanying decrease in rectal bleeding score of *1 or absolute rectal bleeding subscore of *1) in UC subjects and Harvey - Bradshaw Index (HBI) scores (defined as a *3-point decreased in HBI score from baseline) in CD subjects (randomized early terminator CD subjects only [defined as randomized CD subjects withdrawn from the parent study between Week 6 and Week 52]).

* Proportion of subjects with clinical remission during long-term vedolizumab SC treatment using partial Mayo scores (defined as a partial Mayo score of *2 and no individual subscore >1 point) in UC subjects and Harvey-Bradshaw Index (HBI) scores (defined as a HBI score of *4 points) in CD subjects

Study description

Background summary

Current treatments have been effective for many patients with inflammatory bowel disease but have numerous limitations for patients with moderately to severely active disease. These limitations indicate that there is a significant need for safer and more effective therapies. Vedolizumab (also called MLN0002) is a humanized immunoglobulin (Ig) G1 mAb developed as a treatment for UC and CD that acts as a gut-selective immunomodulator. Vedolizumab SC is a new liquid presentation that has been developed for subcutaneous administration to enable self-injection by patients or their caregivers. The aim of the current study is to gather data on the long-term safety and efficacy of vedolizumab SC in subjects with ulcerative colitis (UC) or Crohn*s disease (CD).

Study objective

Primary:
* To obtain data on long term safety and tolerability on vedolizumab SC in subjects with Ulcerative Colitis (UC) or Crohn's Disease (CD).

Secondary:
* To obtain data on adverse events of special interest (AESIs; serious infections including opportunistic infection such as PML, liver injury, malignancies, injection site reactions or systemic reactions and hypersensitivity) in UC and CD subjects receiving long-term vedolizumab SC treatment.
* To obtain data on maintaining clinical response and clinical remission in UC and CD subjects receiving long-term vedolizumab SC treatment
* To obtain data on patient reported outcomes (PROs) including quality of life and work productivity and activity, in UC and CD subjects receiving long-term vedolizumab SC treatment
* To obtain data on time to major UC and CD-related events (hospitalizations, bowel surgeries, and procedures) in UC and CD subjects receiving long-term vedolizumab SC treatment

Study design

This is a phase 3b open-label extension (OLE) study to gather the long-term safety and efficacy of vedolizumab subcutaneous (vedolizumab SC) in subjects with ulcerative colitis (UC) or Crohn*s disease (CD). All enrolled subjects will receive vedolizumab SC 108 mg. From this OLE study of vedolizumab SC therapy, data regarding the occurrence of important clinical events resulting from chronic vedolizumab SC administration will be obtained. Important clinical events including those related to safety and adverse events of special interest

(AESIs; serious infections including opportunistic infection such as PML, liver injury, malignancies, injection site reactions or systemic reactions and hypersensitivity) as well as efficacy (eg, maintenance of clinical remission/ clinical response, quality of life, and various other patient-reported outcome [PRO] measures) will be collected. This study will provide long-term safety data for vedolizumab SC dosing to complement the safety data gathered from Study MLN0002SC-3027 in UC subjects and Study MLN0002SC-3031 in CD subjects.

Intervention

The first dose of vedolizumab SC in this OLE study will be timed according to the last
dose of study drug in the MLN0002SC-3027 or MLN0002SC-3031 studies, to maintain the trough serum concentration above the level associated with clinical efficacy of
vedolizumab IV in UC and CD subjects.

Subjects with UC or CD who completed the Maintenance Period (Week 52 assessment) will receive vedolizumab SC 108 mg Q2W.

Subjects with UC or CD who withdrew early from the Maintenance Period due to disease worsening or need for rescue medications will receive vedolizumab SC 108 mg QW.

Subjects with UC and CD who did not achieve a clinical response at Week 6 but who did achieve a clinical response at Week 14 after having received a 3rd vedolizumab IV infusion at Week 6 will receive vedolizumab SC 108 mg Q2W.

Study burden and risks

Subjects will need to visit the hospital 3 times during the first 8 weeks and then once every 8 weeks. The total study duration will vary by subject depending on continued benefit. During the treatment period subjects will self-inject the study drug every week or every 2 weeks, depending on their response in the prior study. Subjects will need to maintain a daily electronic diary throughout the study and complete 3 questionnaires every 24 weeks. Procedures will include physical exams, ECGs and collection of blood, stool and urine samples.
The most common side effects of the study drug, reported in more than 10% of patients, include common cold, headache, joint pains and worsening of Crohn*s disease in patients with Crohn*s disease. To address the theoretical risk of the development of PML in subjects treated with vedolizumab, a Risk Minimization Action Plan for PML will be implemented.

Contacts

Public
Takeda

Kingdom Street 1
London W2 6BD
GB
Scientific
Takeda

Kingdom Street 1
London W2 6BD
GB

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

The subject has previously participated in Study MLN0002SC-3027 or MLN0002SC-3031, and, in the opinion of the investigator, tolerated the study drug well. Subjects who withdraw early from Study MLN0002SC-3027 or MLN0002SC-3031 must have withdrawn due to treatment failure (ie, as determined by disease worsening or need for rescue medications from Week 14 of the respective study) during the Maintenance Period.

Exclusion criteria

* The subject required surgical intervention for UC or CD during or after participation in Study MLN0002SC-3027 or MLN0002SC-3031, currently requires

surgical intervention for UC or CD, or is anticipated to require surgical intervention for UC or CD during this study.
* The subject has withdrawn from Study MLN0002SC-3027 or MLN0002SC-3031 due to a study drug-related adverse event (AE).

Study design

Design

Study phase:	3
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	13-06-2017
Enrollment:	12
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	-
Generic name:	Vedolizumab SC

Ethics review

Approved WMO

Date:	27-01-2016
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Approved WMO

Date:	25-05-2016
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	01-02-2017
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	01-03-2017
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	18-07-2017
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	04-04-2019
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	05-04-2019
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	18-10-2019
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	20-07-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek

	(Assen)
Approved WMO Date:	24-07-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	08-12-2020
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	10-03-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	23-03-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2015-000482-31-NL

Register	ID
ClinicalTrials.gov	NCT02620046
CCMO	NL55765.056.16